Agilent Technologies (A) stock
Health Care · Life Sciences Tools & Services
Agilent Technologies (A) is a Life Sciences Tools & Services company in the Health Care sector, headquartered in Santa Clara, California. As of October 23, 2026, A closed at $173.07, a market capitalization of $48.80 billion, the 235th largest company in the S&P 500. Over the last twelve months it generated $7.37 billion in revenue (+8% year over year) and $1.27 billion in free cash flow. The stock trades at 34.1x trailing earnings and 25.7x forward earnings.
- 1-year total return: +18.2% (dividends reinvested)
- 5-year return: +2.6% a year
- 52-week range: $108.35 – $179.10
- Gross margin 53.6%, operating margin 25.6%
- Dividend yield: 0.59%, 13 straight years of increases
- FI Handbook report card: B- across 10 metrics
- 31st largest of 60 Health Care stocks in the S&P 500
A price chart
1Y price change: +17.4% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| A | +4.8% | +28.1% | +18.2% | +17.4% | +2.6% | +15.2% | +7.3% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1999.
A key statistics
- Market cap
- $48.8B
- #235 in S&P 500
- P/E (TTM)
- 34.1x
- Forward P/E
- 25.7x
- EPS (TTM)
- $5.07
- Revenue (TTM)
- $7.4B
- +8%
- Free cash flow
- $1.3B
- Gross margin
- 53.6%
- Operating margin
- 25.6%
- Return on equity
- 21.0%
- Dividend yield
- 0.59%
- 52-week range
- $108.35 – $179.10
- Beta
- 1.21
- Price / sales
- 6.6x
- EV / EBITDA
- 24.6x
- Debt / equity
- 0.56x
- Employees
- 18,200
A report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth8.1%C
- Gross margin53.6%B
- Operating margin25.6%B
- FCF margin17.2%B
- Return on equity21.0%B
- Net debt / EBITDA1.1xC
- Forward P/E25.7xC
- PEG ratio1.3xB
- Shareholder yield1.5%D
- Share count change / yr-1.8%B
Agilent Technologies financials
Revenue went from $4.2B in fiscal 2016 to $6.9B in fiscal 2025, growing 5.7% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2B | $4.5B | $4.9B | $5.2B | $5.3B | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Gross profit | $2.2B | $2.4B | $2.7B | $2.8B | $2.8B | $3.4B | $3.7B | $3.5B | $3.5B | $3.6B |
| Operating income | $615.0M | $807.0M | $904.0M | $941.0M | $846.0M | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net income | $462.0M | $684.0M | $316.0M | $1.1B | $719.0M | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| EPS (diluted) | $1.40 | $2.10 | $0.97 | $3.37 | $2.30 | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 |
| Free cash flow | $654.0M | $713.0M | $910.0M | $866.0M | $802.0M | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| Buybacks | $434.0M | $194.0M | $422.0M | $723.0M | $469.0M | $788.0M | $1.1B | $575.0M | $1.1B | $425.0M |
| Dividends paid | $150.0M | $170.0M | $191.0M | $206.0M | $222.0M | $236.0M | $250.0M | $265.0M | $274.0M | $282.0M |
| Diluted shares | 329.0M | 326.0M | 325.0M | 318.0M | 312.0M | 307.0M | 300.0M | 296.0M | 291.0M | 285.0M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into A?
A reverse DCF asks what growth the current price requires. With an enterprise value of $51.2B and $1.3B of trailing free cash flow, Agilent Technologies needs to grow free cash flow about 28.8% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 7.5% a year over the last five years.
P/E ratio history
Current 37.9x vs. median 29.0x (10th–90th percentile 12.5x–52.7x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
A dividend
- Dividend yield
- 0.59%
- Annual dividend
- $1.02
- Years of increases
- 13
- 5-yr dividend growth
- 6.6%
- per year
- Payout ratio
- 20%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
A analyst price targets
19 analysts' average 12-month target is $181.63 (+5% vs. $173.07). Targets range from $155.00 to $200.00. 67% rate it a buy.
A earnings
Next report: November 25, 2026. Agilent Technologies has beaten EPS estimates 2 quarters in a row. Last quarter's revenue was $1.9B (+8% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 26, 2026 | $1.49 | $1.62 | +9.0% |
| May 27, 2026 | $1.41 | $1.49 | +5.8% |
| Feb 25, 2026 | $1.37 | $1.36 | -0.6% |
| Nov 24, 2025 | $1.58 | $1.59 | +0.4% |
| Aug 27, 2025 | $1.37 | $1.37 | +0.2% |
| May 28, 2025 | $1.26 | $1.31 | +3.6% |
| Feb 26, 2025 | $1.27 | $1.31 | +3.0% |
| Nov 25, 2024 | $1.41 | $1.46 | +3.9% |
Stocks like A
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 TMO Thermo Fisher Scientific | -0.40% | +18% | $249.1B | 35.5x | Compare |
 DHR Danaher | +0.33% | +4% | $162.0B | 38.2x | Compare |
 IQV IQVIA | +0.37% | +27% | $46.0B | 34.7x | Compare |
 WAT Waters | -0.42% | +28% | $44.5B | 114.9x | Compare |
 ILMN Illumina | +0.01% | +170% | $40.7B | 50.3x | Compare |
 MTD Mettler-Toledo International, I | -0.85% | +16% | $33.5B | 37.6x | Compare |
 CRL Charles River Laboratories Inte | +1.68% | +81% | $16.6B | — | Compare |
 TECH Bio-Techne | -0.10% | +10% | $11.4B | 62.5x | Compare |
A news
- Agilent acquires Proscia in deal worth up to $270m · Oct 14, 2026
- Global Metabolomics Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.3% CAGR as Thermo Fisher, Bruker, Agilent, and Metabolon Accelerate AI Diagnostics · Oct 14, 2026
- Agilent to buy Proscia for $240M · Oct 14, 2026
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence · Oct 13, 2026
- Is Agilent Technologies (A) Outperforming Other Medical Stocks This Year? · Oct 12, 2026
A stock FAQ
What is A's market cap?
Agilent Technologies's market capitalization is $48.80 billion as of October 23, 2026, ranking 235th in the S&P 500.
What is A's P/E ratio?
A trades at a trailing price-to-earnings ratio of 34.1x and a forward P/E of 25.7x. Its median P/E over the period we track is 29.0x.
Does A pay a dividend?
Yes. Agilent Technologies pays $1.02 per share a year, a 0.59% yield. It has raised its dividend 13 years in a row. Dividends grew 6.6% a year over the last five years.
How much has A stock returned?
Including reinvested dividends, A returned +18.2% over one year, +2.6% a year over five years, +15.2% a year over ten years through October 23, 2026.
Is A stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Agilent Technologies must grow free cash flow about 29% a year for the next decade. Its free cash flow grew 8% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the A price target?
19 analysts cover A with an average 12-month price target of $181.63, +5% from the current price. 67% of them rate it a buy.
When does A report earnings?
Agilent Technologies is expected to report earnings on November 25, 2026. It has beaten EPS estimates 2 quarters in a row.
How many employees does Agilent Technologies have?
Agilent Technologies has about 18,200 full-time employees, or $405,055 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology